Medical Oncology
Outline
The Department of Medical Oncology is a clinical department that was established in the School of Medicine in 2005. The department has kept pace with the developments of the 21st century. Cancer is the leading cause of death in Japan. Medical oncology, or clinical oncology, is a multidisciplinary medical field that specializes in tumor-agnostic treatments, focusing on pharmacotherapeutics. Over the last 20 years, several new drugs have been developed, such as molecularly targeted drugs. Since the discovery of cancer-specific biomarkers, these drugs have become the mainstream medicine for standard drug therapies. More recently, a series of new drugs called immune checkpoint inhibitors, which can prevent cancer cells from suppressing the immune system, have become available. These innovative, tumor-agnostic drugs are now proving to be very effective in cancer treatments. Cancer develops due to genetic defects. With the rapid progress in genetic analysis technology using next-generation sequencers, cancer multi-gene panel testing, which can comprehensively analyze multiple cancer-related genes at once, is now covered by insurance. Currently, cancer multi-gene panel testing is clinically applied to personalized medicine in cancer treatment, providing optimal therapeutic drugs for different types of cancer. In the future, it is expected that this technology will be further applied to cancers with unmet medical needs and no cure, including refractory cancers and rare cancers, and will also lead to the development of new biomarkers and therapeutic drugs.
e-mail: cancer@kanazawa-med.ac.jp
Faculty
Professor
Research Achievements
Miwa T, Ikeda K, Ishibashi T, Kobayashi M, Kondo K, Matsuwaki Y, Ogawa T, Shiga H, Suzuki M, Tsuzuki K, Furuta A, Motoo Y, Fujieda S, Kurono Y. Clinical practice guidelines for the management of olfactory dysfunction - Secondary publication. Auris Nasus Larynx 2019 May 7. pii: S0385-8146(19)30118-X.
Amano K, Ichikura K, Hisamura K, Motomatsu Y, Matsushima E. Factors Associated with Social Support Needs of Spouses of Patients with Cancer: Online Survey. International Journal of Clinical Medicine, 2019; 10: 270-292.
Motoo Y, Yukawa K, Arai I, Hisamura K, Tsutani K. Use of complementary and alternative medicine in Japan: a cross-sectional internet survey using the Japanese version of the International Complementary and Alternative Medicine Questionnaire. JMA Journal, 2019; 2(1): 35-46.
Motoo Y. Editorial. Nivolumab-related sclerosing cholangitis in gastric cancer. Intern Med 2019 Jan 10.
Motoo Y, Yukawa K, Hisamura K, Tsutani K, Arai I. Internet survey on the provision of complementary and alternative medicine in Japanese private clinics: a cross-sectional study. J Integr Med 2019; 17(1): 8-13.
External Research Funding
2019 Japan Agency for Medical Research and Development (AMED) Grant-in-Aid. Motoo Y. Research on information, current status, and safety/efficacy of community-based, disease-preventing or health-promoting programs utilizing integrative medicine as social models
2018-2019 Japan Agency for Medical Research and Development (AMED) Grant-in-Aid (Translational Research Promotion: Seeds A). Yasumoto K. Development of innovative therapies for scirrhous gastric carcinoma with regulation of HGF/MET axis.
2017-2019 Grant-in-Aid for Scientific Research (C). Yasumoto K. Development of innovative targeted therapy by essential control of the HGF/MET axis for scirrhous gastric cancer
2018-2021 Grant-in-Aid for Scientific Research (C). Hisamura K. Research on psychosocial support for middle-aged and elderly patients with cancer who live alone and have no family caregivers
The 2018 second semester home care subsidy of Yuubi Memorial Foundation research grant. Hisamura K. Study on building a community-based support system for appearance changes among cancer survivors.